Migraine, Cyclic Vomiting Syndrome, and Other Gastrointestinal Disorders

Yu, Elliot; S, Yasodara Priyadharsini S; Venkatesan, Thangam

doi:10.1007/s11938-018-0202-2

Cited by 23 publications

(30 citation statements)

References 101 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Newer therapies that target CGRP receptors have shown efficacy in migraine prophylaxis in Phase IIb and III trials, and erenumab and fremanezumab have recently been approved by the FDA for this indication . These medications have not been studied in CVS, but may be effective in those with or without migraine headaches given the strong link between CVS and migraine . Goals of future prospective investigations would be to confirm utility of any of these proposed therapies in reducing the frequency, duration, or severity of CVS attacks and to better define which patient subsets are likely to respond to different treatment options.…”

Section: Future Research Directions In Cvsmentioning

confidence: 99%

“…Prior to construction of this Consortium, research in gastroparesis exhibited many features similar to those which plague current CVS investigations. Since the consortium began recruitment, more than 1000 gastroparesis patients have been enrolled in longitudinal databases and three major prospective studies enrolling more than 100 patients each have been conducted . Longitudinal demographic and clinical data relating to age, sex, symptom duration, traumatic events preceding symptom onset such as early adverse life events, both physiological and psychological, comorbid illnesses, associated psychological dysfunction, disease‐specific quality of life, healthcare resource utilization (including hospitalizations and emergency department visits), and prior and ongoing treatments have been systematically collected in all enrolled patients.…”

Section: Future Research Directions In Cvsmentioning

confidence: 99%

See 1 more Smart Citation

Cyclic vomiting syndrome: Pathophysiology, comorbidities, and future research directions

Hasler

Levinthal

Tarbell

et al. 2019

Neurogastroenterology Motil

Self Cite

View full text Add to dashboard Cite

Cyclic vomiting syndrome (CVS) is characterized by severe episodic emesis in adults and children. Cannabinoid hyperemesis syndrome is an increasingly recognized CVS‐like illness that has been associated with chronic cannabis use. There are significant gaps in our understanding of the pathophysiology, clinical features, comorbidities, and effective management options of CVS. Recommendations for treating CVS are based on limited clinical data, as no placebo‐controlled, randomized trials have yet been conducted. Diseases associated with CVS, including migraine, mitochondrial disorders, autonomic dysfunction, and psychiatric comorbidities, provide clues about pathophysiologic mechanisms and suggest potential therapies. We review our current understanding of CVS and propose future research directions with the aim of developing effective therapy. Establishing a multicenter, standardized registry of CVS patients could drive research on multiple fronts including developing CVS‐specific outcome measures to broaden our understanding of clinical profiles, to serve as treatment end points in clinical trials, and to provide a platform for patient recruitment for randomized clinical trials. Such a robust database would also facilitate conduct of research that aims to determine the underlying pathophysiological mechanisms and genetic basis for CVS, as well as identifying potential biomarkers for the disorder. Soliciting government and industry support is crucial to establishing the necessary infrastructure and achieving these goals. Patient advocacy groups such as the Cyclic Vomiting Syndrome Association (CVSA), which partner with clinicians and researchers to disseminate new information, to promote ongoing interactions between patients, their families, clinicians, investigators, to support ongoing CVS research and education, must be an integral part of this endeavor.

show abstract

Section: Future Research Directions In Cvsmentioning

confidence: 99%

Section: Future Research Directions In Cvsmentioning

confidence: 99%

Cyclic vomiting syndrome: Pathophysiology, comorbidities, and future research directions

Hasler

Levinthal

Tarbell

et al. 2019

Neurogastroenterology Motil

Self Cite

View full text Add to dashboard Cite

show abstract

“…4 Symptoms such as nausea, vomiting, abdominal pain, headache, and photophobia can be seen in both disorders. 5 Due to the similarities between these two disorders, the management of CVS overlaps with migraine. Prophylactic therapies including antidepressants and anticonvulsants have been shown to be effective in preventing migraines and CVS attacks.…”

Section: Introductionmentioning

confidence: 99%

“…3 The pathogenesis of CVS remains unclear, but the close relationship between migraine and CVS suggests that they share a common pathophysiology. 4,5 Clinically, CVS and migraine have similarities: both are episodic in nature, are triggered by stress, and have a prodromal phase when patients can use medications to try and abort an episode. 4 Symptoms such as nausea, vomiting, abdominal pain, headache, and photophobia can be seen in both disorders.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Sumatriptan as abortive treatment in cyclic vomiting syndrome: A cross-sectional study

Lin

Zhou

Venkatesan

2020

Cephalalgia Reports

Self Cite

View full text Add to dashboard Cite

Cyclic vomiting syndrome (CVS) is characterized by episodic vomiting and shares similarities with migraine headache. Guidelines recommend using triptans as abortive therapy in CVS, but there are limited data on its efficacy. Methods: We thus sought to characterize sumatriptan use and performed a cross-sectional study of adults with CVS episodes within the previous 6 months. Questionnaires about demographics, clinical characteristics, and response to sumatriptan (defined as >50% reduction in symptoms) were administered via e-mail. We investigated differences between responders and nonresponders, using χ 2 and Student’s t test. Results: Of 101 participants (age 41 ± 15 years, 74% female, 83% Caucasian), 39 (38%) used sumatriptan during their last CVS attack. Most reported an improvement in nausea (55%), vomiting (59%), and abdominal pain (43%) within 2 h and at 24 h (67%, 73%, and 67%) respectively. Eighteen (46%) reported that sumatriptan helped them avoid emergency department visits and 20 (51%) avoided being hospitalized. Nonresponse to sumatriptan was associated with depression ( p = 0.01), current cannabis use ( p = 0.02), use of benzodiazepines ( p = 0.04), and opioids (0.02) during an episode. No serious side effects were noted. Conclusions: Sumatriptan use reduced symptoms of CVS but did not abort them. Prospective studies to determine its independent effects are needed.

show abstract

Cyclic Vomiting Syndrome, Abdominal Migraine, and Chronic Nausea

Kovacic

2022

Pediatric Neurogastroenterology

View full text Add to dashboard Cite

Migraine, Cyclic Vomiting Syndrome, and Other Gastrointestinal Disorders

Cited by 23 publications

References 101 publications

Cyclic vomiting syndrome: Pathophysiology, comorbidities, and future research directions

Cyclic vomiting syndrome: Pathophysiology, comorbidities, and future research directions

Sumatriptan as abortive treatment in cyclic vomiting syndrome: A cross-sectional study

Cyclic Vomiting Syndrome, Abdominal Migraine, and Chronic Nausea

Contact Info

Product

Resources

About